Derma Sciences' MEDIHONEY(R) to be Featured at American Professional Wound Care Association Conference

Wednesday, April 7, 2010 Press Release
Email Print This Page Comment
Font : A-A+

PRINCETON, N.J., April 6 Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, announced today that the American Professional Wound Care Association plans to spotlight Derma's MEDIHONEY® Wound and Burn Dressings at the Association's 10th Annual Conference, APWCA 2010, in Philadelphia this week. MEDIHONEY® will be featured during a breakfast symposium on Friday, April 9, titled "Anti-Microbial Dressings: New Concepts."

In addition, the company will present six posters at the conference, each showcasing successful MEDIHONEY® case studies. The poster list is as follows:

MEDIHONEY®, Derma Sciences' line of novel patented dressings, is comprised of a high percentage of Active Leptospermum Honey. This unique type of honey has been shown in a randomized controlled study to increase the rate of chronic ulcer healing versus other advanced wound care dressings. MEDIHONEY® dressings are ideal for the management of non-chronic and hard-to-heal wounds including diabetic ulcers, pressure ulcers, leg ulcers, burns and post-operative wounds.

Derma Sciences Chairman and CEO, Ed Quilty, stated, "We are honored to play such a visible role at APWCA 2010 and believe it will be an excellent opportunity to provide wound care professionals with new information on how MEDIHONEY® can be used to treat hard-to-heal wounds. The product is a key part of Derma Sciences' growth strategy."

The conference runs from April 8 through 11 at the Sheraton Philadelphia City Center.

About Derma Sciences, Inc.

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY®, is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Other key novel products introduced into the $14 billion global wound care market include XTRASORB(TM) for better management of wound exudate, and BIOGUARD(TM) for infection prevention. Derma also has in development DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction. DSC127, an angiotensin analog, has shown positive healing results in multiple pre-clinical animal models. One possible mode of action of the drug is the up-regulation of mesenchymal stem cells at the wound site. Derma expects to announce the key efficacy endpoint result from this study during Q3 of 2010.

For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.

-- "Active Leptospermum Honey and Negative Pressure Wound Therapy for Non-Healing Post-Surgical Wounds" by Edna Acuna, MD, of Dallas, TX -- "Evidence Based Practice for Pediatric Wound Care: Utilizing Active Leptospermum Honey as a Primary Dressing in Chronic Wounds" by Charleen Deo, RN, CWOCN, Lucile Packard Children's Hospital, of Palo Alto, CA -- "Evidence Based Practice: Active Leptospermum Honey Dressings for Use in an Indigent Outpatient Wound Care Clinic" by Diane Maggio, RN, CWOCN, of Atlantic City, NJ -- "Active Leptospermum Honey for Pediatric Wound Care: Moving Evidence into Practice for Pediatric Wound Care" by Roxana Reyna, RNC, WCC, Driscoll Children's Hospital, of Corpus Christi, TX -- "The Clinical Benefits of Active Leptospermum Honey: Oncologic Wounds" by Debbie Segovia, RN, MSN, CWOCN, Cancer Treatment Centers of America, of Tulsa, OK -- "Selection of a Cost-effective Debriding Alternative to a Pharmaceutical Enzymatic Agent at One County Long Term Care Facility" by Mary Webb, San Mateo Medical Center, of San Mateo, CA

SOURCE Derma Sciences, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook